An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.

Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.

Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.